US messenger RNA (mRNA) Moderna (Nasdaq: MRNA) today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214, demonstrating its superiority of the biotech’s original COVID-19 vaccine Spikevax.
Moderna notes that 90 days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50µg booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50µg booster dose of mRNA-1273 (which is marketed under the trade name Spikevax, in all participants regardless of prior infection. Superior performance against Omicron BA.1 was also durable, with higher antibody titers sustained through three months. Spikevax recorded sales of over $7 billion last year.
Markets, however, were unimpressed, as Moderna’s shares were down 6.9% at $124.84 by early afternoon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze